Firstly, we pretreated CLL cells with a JAK1/2 inhibitor, INCB018424, leading to the blockade of the intracellular signaling molecules downstream to IFN-γ. This evidence concerns the gene JAK1 and B-cell chronic lymphocytic leukemia.